Health Consultation

PUBLIC COMMENT RELEASE

ASSESSMENT OF CANCER INCIDENCE IN COUNTIES ADJACENT TO OAK RIDGE RESERVATION, U.S. DEPARTMENT OF ENERGY

OAK RIDGE, ANDERSON COUNTY, TENNESSEE

EPA FACILITY ID: TN1890090003

MARCH 1, 2006

COMMENT PERIOD END DATE: APRIL 14, 2006

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry Division of Health Studies Atlanta, Georgia 30333

Health Consultation: A Note of Explanation

An ATSDR health consultation is a verbal or written response from ATSDR to a specific request for information about health risks related to a specific site, a chemical release, or the presence of hazardous material. In order to prevent or mitigate exposures, a consultation may lead to specific actions, such as restricting use of or replacing water supplies; intensifying environmental sampling; restricting site access; or removing the contaminated material.

In addition, consultations may recommend additional public health actions, such as conducting health surveillance activities to evaluate exposure or trends in adverse health outcomes; conducting biological indicators of exposure studies to assess exposure; and providing health education for health care providers and community members. This concludes the health consultation process for this site, unless additional information is obtained by ATSDR which, in the Agency's opinion, indicates a need to revise or append the conclusions previously issued.

You May Contact ATSDR TOLL FREE at 1-888-42ATSDR or Visit our Home Page at: http://www.atsdr.cdc.gov

HEALTH CONSULTATION

PUBLIC COMMENT RELEASE

ASSESSMENT OF CANCER INCIDENCE IN COUNTIES ADJACENT TO OAK RIDGE RESERVATION, U.S. DEPARTMENT OF ENERGY

OAK RIDGE, ANDERSON COUNTY, TENNESSEE

EPA FACILITY ID: TN189009003

Prepared by:

Agency for Toxic Substances and Disease Registry Division of Health Studies

This information is distributed solely for the purpose of pre-dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

INTRODUCTION	5
MATERIALS AND METHODS	5
Geographic Area	5
Tennessee Cancer Registry	5
Cancer Incidence Data	6
Statistical Methods	6
RESULTS	7
Anderson County	7
Blount County	7
Knox County	8
Loudon County	8
Meigs County.	9
Morgan County	9
Rhea County	9
Roane County	10
DISCUSSION	10
Advantages	10
Limitations	10
CONCLUSIONS	11
COMMUNITY HEALTH CONCERNS	13
List of Tables	17
Table 1: Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Anderson Count 1991–2000 (Females).	l ty 18
Table 2: Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Anderson Count 1991–2000 (Males)	l ty 19
Table 3: Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Blount County 1991–2000 (Females)	l 20
Table 4: Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Blount County 1991–2000 (Males)	l 21

TABLE OF CONTENTS

Table 5:	Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Knox County 1991–2000 (Females)	22
Table 6:	Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Knox County 1991–2000 (Males)	24
Table 7: 1	Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Loudon County 1991–2000 (Females)	26
Table 8: 1	Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Loudon County 1991–2000 (Males)	27
Table 9: 1	Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Meigs County 1991–2000 (Females)	28
Table 10:	Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Meigs County 1991–2000 (Males)	29
Table 11:	Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Morgan County 1991–2000 (Females)	30
Table 12:	Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Morgan County 1991–2000 (Males)	31
Table 13:	Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Rhea County 1991–2000 (Females)	32
Table 14:	Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Rhea County 1991–2000 (Males)	33
Table 15:	Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Roane County 1991–2000 (Females)	34

Table 16: Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Roane County 1991–2000 (Males)	35
1))1=2000 (Wates)	
APPENDIX A	36
Most Commonly Diagnosed Cancers	37
APPENDIX B	38
Map of Counties Included in Analysis	39
APPENDIX C	40
List of Cancer Sites Included in Analysis	41
APPENDIX D	42
Methods for Analyzing and Interpreting Cancer Incidence Data	43
REFERENCES	44

INTRODUCTION

Residents of the communities surrounding the U.S. Department of Energy's Oak Ridge Reservation in Oak Ridge, Tennessee, are concerned about a perceived increase in cancer in their area. To address these concerns, the Oak Ridge Reservation Health Effects Subcommittee (ORRHES) requested that the Agency for Toxic Substances and Disease Registry (ATSDR) and the Tennessee Department of Health Cancer Registry assess the incidence of cancer in this area. Cancer incidence refers to newly diagnosed cases of cancer that are reported to the Tennessee Cancer Registry. This assessment was conducted using data that are already collected, providing a general picture of the occurrence of cancer in the area.

The purpose of this report is to give residents of the Oak Ridge area information about cancer rates in their county compared with the State of Tennessee. This assessment examined cancer rates at the population level and cannot be used to evaluate individual risk. Also, it cannot be used to determine why an individual develops cancer, because (1) information on individual exposure data or risk factors is not available, (2) cancer takes time to develop, usually 20–40 years, (3) different types of cancer have different causes, and (4) we don't know the causes of most types of cancer. However, scientific studies have identified risk factors for various cancers. A risk factor is something that may increase an individual's risk of developing a specific type of cancer. Cancer risk factors include heredity, geographic area, diet, occupational exposures, environmental factors, tobacco smoke, sexual practices, and alcohol consumption. Appendix A contains information about the most commonly diagnosed cancers.

MATERIALS AND METHODS

Geographic Area

The geographic area for this assessment of cancer incidence includes eight counties surrounding the Oak Ridge Reservation: Anderson, Blount, Knox, Loudon, Meigs, Morgan, Rhea, and Roane. Figure 1 in Appendix B shows the locations and boundaries of the eight counties.

Tennessee Cancer Registry

All cancer data were provided by the Tennessee Cancer Registry (TCR) of the Tennessee Department of Health. The TCR has maintained data on cancer incidence (new cases of cancer) for the State of Tennessee since 1986. Cancer incidence data are acquired under the Tennessee Cancer Reporting System Act of 1983 (T.C.A. 68-1-1001 et seq.), which requires that all general and specialty hospitals, clinical laboratories, and cancer treatment centers report all cases of cancer to the Tennessee Department of Health. Every inpatient or outpatient case diagnosed with or treated for cancer must be reported to the TCR within 6 months of the diagnosis date.

The TCR relies on each institution to supply data on the cancer cases. The number of expected reports from each institution is monitored, however, and the TCR contacts facilities that fail to report. The number of reports expected is based on national trends and mortality data.

The registry information available for each newly diagnosed cancer case is abstracted from the patient's medical record and includes demographic and medical data on each individual cancer patient such as name, address at time of diagnosis, primary cancer site, histology type, date of diagnosis, age at diagnosis, birthdate, race, sex, and registry identification number. To ensure that reported data are complete and accurate, TCR staff members perform case-finding and other quality control checks at these institutions. All abstracts are reviewed for completeness of required items, and if discrepancies suggest a reporting error, the TCR contacts the registrars at the reporting facility for clarification and changes. Currently all abstracts must pass the edits recommended by the North American Association of Central Cancer Registries.

Cancer Incidence Data

This assessment used cancer incidence data supplied by the TCR for the years 1991–2000. The TCR has determined that these data are approximately 80% complete. A "case" was defined as a diagnosis of a new primary malignant cancer in an individual residing in one of the selected counties. Analysis was conducted for 42 cancer types, listed in Appendix C.

Statistical Methods

The procedure for analyzing and interpreting cancer incidence data is to compare the number of cancer cases in the population living in the area of concern with a reference population to determine whether an excess of a particular type of cancer exists. Ratios are used to compare the observed number of cancer cases with the "expected" number of cases. The expected number of cancer cases is calculated based on the observed occurrence in a reference population. For this analysis, the area of concern consists of eight counties surrounding Oak Ridge, Tennessee, and the reference population is the population of the state of Tennessee as a whole. For each county, the ratio of the observed to the expected number of cancer cases was examined for males and females, and the information was further standardized to control for the effects of race and age. Standardized or adjusted rates are used to control for demographic differences between populations being compared. These adjusted ratios are referred to as the standardized incidence ratio (SIR).

Specifically, the SIR is the observed number of cases divided by the expected number of cases. A ratio of 1.0 indicates that the number of cases observed in the population being evaluated is equal to the number of cases expected based on the rate of disease in the reference population. A ratio greater than 1.0 indicates that more cases occurred than expected; and a ratio less than 1.0 indicates that fewer cases occurred than expected. Accordingly, a ratio of 1.5 is interpreted as one-and-a-half times as many cases as the expected number, and a ratio of 0.9 indicates nine-tenths as many cases as the expected number. Results were considered statistically significant if the confidence interval did not include 1.0, and results were considered borderline statistically significant if either the lower or upper limit of the confidence interval was 1.0. More detailed information regarding the calculation and interpretation of SIRs, including statistical significance, is included in Appendix D.

RESULTS

ATSDR analyzed the data for 42 cancer types in the eight counties surrounding the Oak Ridge Reservation (Anderson, Blount, Knox, Loudon, Meigs, Morgan, Rhea, and Roane). Tables 1–16 present the results of the analyses for cancer types with more than 5 observed cases. The tables present the results for each county individually by gender. For reasons of confidentiality, the TCR requires that more than 5 cases be observed for results to be reported.

Anderson County

During the period of 1991–2000, 3501 new cases of cancer were reported in Anderson County. Of these, 1682 occurred in females and 1819 occurred in males. The most frequently reported cancers in this county among females were breast, colon, and lung cancer, and among males were colon, bladder, lung, and prostate cancer.

Table 1 shows the numbers of observed and expected cancer incidence cases in Anderson County for females based on Tennessee State cancer incidence rates. Breast and ovarian cancer occurred more often than expected, although these results were of borderline statistical significance. No significant excess of the remaining types of cancer was observed among females in this county during this same time period. Melanomas occurred significantly less often than expected among females during the 10-year time period evaluated.

A significantly greater than expected number of bladder cancer cases were observed among males residing in Anderson County compared with the state of Tennessee, as shown in Table 2. Colon and lung cancer occurred more often than expected among males during this time period, although the results were of borderline statistical significance. No significant excess of the remaining types of cancer was observed in males during this time period. Melanomas occurred significantly less often than expected in males during the 10-year time period evaluated.

Blount County

During the period of 1991–2000, 4413 new cases of cancer were reported in Blount County. Of these, 2072 occurred in females and 2341 occurred in males. The most frequently reported cancers in this county among females were breast, colon, and lung cancer, and among males were colon, bladder, lung, and prostate cancer.

Table 3 shows the observed and expected numbers of cancer incidence cases in Blount County for females based on Tennessee State cancer incidence rates. Melanoma occurred significantly more often than expected among females during the 10-year time period evaluated. No significant excess of the remaining types of cancer was observed among females in this county during this same time period. Lung, corpus uteri and thyroid gland cancer occurred significantly less often than expected. Ovarian, breast, and colon cancer occurred less often than expected among females, although these results were of borderline statistical significance.

Cancer incidence occurred at about expected rates for males in Blount County when compared with the state of Tennessee, as shown in Table 4. Melanomas occurred more than expected among males, although this result was of borderline statistical significance. No significant excess of any type of cancer was observed among males in this county. Colon, lung, prostate, and tongue cancer occurred less often than expected among males, although these results were of borderline statistical significance.

Knox County

During the period of 1991–2000, 15,886 new cases of cancer were reported in Knox County. Of these, 7951 occurred in females and 7935 occurred in males. The most frequently reported cancers in this county among females were breast, colon, and lung cancer, and among males were colon, bladder, lung, and prostate cancer.

Table 5 shows the observed and expected cancer incidence cases in Knox County for females on based on Tennessee State cancer incidence rates. No significant excess of cancer was observed among females in this county. Breast, colon, lung, and corpus uteri cancer occurred more often than expected, although these results were of borderline statistical significance.

No significant excess of cancer was observed among males in this county, as Table 6 illustrates. Colon, lung, melanoma, soft tissue, and prostate cancer, as well as non-Hodgkin lymphoma, occurred more often than expected, although these results were of borderline statistical significance.

Loudon County

During the period of 1991–2000, 1966 new cases of cancer were reported in Loudon County. Of these, 922 occurred in females and 1044 occurred in males. The most frequently reported cancers in this county among females were breast and lung cancer, and among males were lung and prostate cancer.

Table 7 shows the observed and expected cancer incidence cases in Loudon County for females based on Tennessee State cancer incidence rates. Acute myeloid leukemia (AML) occurred significantly more often than expected among females during the 10-year time period evaluated. Rectum cancer occurred more often than expected among females in this county during this same time period, although these results were of borderline statistical significance.

Tables 8 shows that the overall cancer incidence rates for males were about that expected when compared with rates for the state of Tennessee. No significant excess in cases of cancer of any type was observed among males in this county. Gum cancer occurred more often than expected, although these results were of borderline statistical significance.

Meigs County

During the period of 1991–2000, 395 new cases of cancer were reported in Meigs County. Of these, 178 occurred in females, and 217 occurred in males. For the majority of cancer types, 5 or fewer cases were reported for either males or females.

No significant excess of cases of any type of cancer was observed among females or males in this county during the 10-year time period evaluated, as shown in Tables 9 and 10. Colon cancer among females occurred significantly less often than expected when compared with cancer incidence rates for the state of Tennessee.

Morgan County

During the period of 1991–2000, 577 new cases of cancer were reported in Morgan County. Of these, 260 occurred in females and 317 occurred in males. The most frequently reported type of cancer in this county among females was breast cancer, and the most frequently reported types among males were lung cancer and prostate cancer.

No significant excess of cases of any type of cancer was observed among females or males in this county during this time period when compared with cancer incidence rates for the state of Tennessee, as Tables 11 and 12 illustrate. Breast cancer in females and colon and prostate cancer in males occurred significantly less often than expected in Morgan County when compared with cancer incidence rates for the state of Tennessee.

Rhea County

During the period of 1991–2000, 1186 new cases of cancer were reported in Rhea County. Of these, 558 occurred in females and 628 occurred in males. The most frequently reported cancers in this county among females were breast, colon, and lung cancer, and among males were lung and prostate cancer.

A significantly greater than expected number of cervical cancer cases were observed among females, as shown in Table 13. No significant excess in cases of the remaining types of cancer was observed in females during this time period. Breast and lung cancer among females occurred less often than expected during this time period, although the results were of borderline statistical significance.

A significantly greater than expected number of cases of cancer of the floor of the mouth and of cancer of the small intestine were observed among males residing in Rhea County when compared with cancer incidence rates for the state of Tennessee, as shown in Table 14. Chronic lymphocytic leukemia occurred more often than expected among males during this time period, although the results were of borderline statistical significance. No significant excess in cases of the remaining types of cancer was observed in males during this time period. Prostate cancer occurred less often than expected during the 10-year time period evaluated, although this result was of borderline statistical significance.

Roane County

During the period of 1991–2000, 2380 new cases of cancer were reported in Roane County. Of these, 1127 occurred in females and 1253 occurred in males. The most frequently reported cancers in this county among females were breast and lung cancer, and among males were colon, lung, and prostate cancer.

Table 15 shows that kidney cancer occurred significantly more often than expected among females in Roane County when compared with cancer incidence rates for the state of Tennessee. No significant excess in cases of the remaining types of cancer was observed among females in this county during this same time period. Pancreatic cancer occurred significantly less often than expected among females during this time period. Breast and colon cancer and non-Hodgkin lymphoma occurred less often than expected among females during the 10-year time period evaluated, although these results were of borderline statistical significance.

No significant excess in cases of any type of cancer was observed in males in Roane County, as shown in Table 16. Lung cancer occurred more often than expected, although this result was of borderline statistical significance. Melanomas and prostate cancer occurred significantly less often than expected among males residing in Roane County when compared with cancer incidence rates for the state of Tennessee.

DISCUSSION

An assessment of cancer incidence gives a general picture of the occurrence of cancer in a community, and it may confirm the presence of excess cancer in a community. However, the cause of elevated rates of a particular cancer cannot be determined by cancer incidence data. Many other risk factors, such as socioeconomic status, occupation, and personal habits (for example, diet and smoking), influence the development of cancer. Information on risk factors was not available and therefore was not analyzed in this assessment of cancer incidence.

Advantages

Advantages of conducting an analysis of this type is that it responds to community members' concern about potential excess of cancer in their county. It also provides specific information about the status of cancer rates in a particular county, and it can be used to identify areas where further public health investigations or actions may be warranted. Analyzing cancer incidence data is better than examining deaths caused by cancer, because people with cancer may not die of their cancer; therefore, information about their cancer would not be captured in the death certificate. Also, making comparisons using the number of people in a county who have been diagnosed with cancer presents a truer picture of cancer rates in a county.

Limitations

Several limitations are associated with the data available for this analysis:

- 1. the data from 1991–2000 are approximately 80% complete;
- 2. some of the reported numbers of specific types of cancer are very small, making the rates unstable; and
- 3. information on risk factors was not available making it impossible to evaluate the potential causes of cancer in the Oak Ridge area or to identify all the risk factors that may have influenced the rate of cancer in the population.

Another limitation of this type of investigation is that cancer is a chronic disease that takes many years to manifest as a clinical disease. The information supplied by the TCR provides an address at the time of diagnosis for each person diagnosed with cancer but does not give information on the length of time a person may have lived at the address before being diagnosed. This lack of information about the length of time a person has resided at an address is an issue with any type of cancer incidence analysis, because population mobility cannot be accounted for. In other words, some reported cases of cancer may be for residents who have recently moved into the area, so including those cases in the data analysis would result in an overcount of cancer cases. Similarly, cancers could have developed among persons who lived in an area in the past but who have moved away. If so, the analysis would have missed these persons, creating an undercount of cancer cases.

CONCLUSIONS

The objective of this analysis was to determine whether elevated rates of cancer are present in the counties around the Oak Ridge Reservation as compared with cancer incidence in the state of Tennessee. The results show that higher rates of some cancers and lower rates of some cancers were found in several of the counties for which data were analyzed, although there was no consistent pattern in cancer occurrence.

The reasons for the higher rates of some cancers are unknown. It is not possible to determine why people in the Oak Ridge area developed cancer, or whether the Oak Ridge facility could be the cause of the higher number of cancers observed, because (1) information on individual exposure data is not available, (2) it takes time for cancer develop, usually 20 to 40 years, (3) different types of cancer have different causes, and (4) the causes of most cancer are unknown. Scientific studies have identified factors that may increase the risk of developing specific types of cancer. Cancer risk factors include heredity, geographic area of residence, diet, environmental causes, tobacco smoke, sexual practices, and alcohol consumption. Increases in rates of cancer reported in certain areas also could be due simply to increased awareness and screening in those areas.

The statistically significant findings from this assessment are as follows:

- 1. For two counties, Meigs and Morgan, limited information was available for the analysis because fewer than 5 cases of several cancer types were reported in those counties during 1991–2000.
- 2. In Anderson County, melanomas occurred less often than expected among males and females, and bladder cancer occurred more often than expected among males.
- 3. In Blount County, lung, thyroid, and corpus uteri cancer occurred less often than expected among females, and melanomas occurred more often than expected among females.
- 4. In Knox County, no type of cancer occurred more often than expected among females or males.
- 5. In Loudon County, acute myeloid leukemia occurred more often than expected among females.
- 6. In Meigs County, colon cancer occurred less often than expected among females.
- 7. In Morgan County, colon and prostate cancers occurred less often than expected among males, and breast cancer occurred less often than expected among females.
- 8. In Rhea County, cancer of the floor of the mouth and cancer of the small intestine occurred more often than expected among males, and cervical cancer occurred more often than expected among females.
- 9. In Roane County, melanomas and prostate cancer occurred less often than expected among males, and pancreatic cancer occurred less often than expected among females. Kidney cancer occurred more often than expected among females.

ANSWERS TO COMMUNITY HEALTH CONCERNS

1. What were the results from this investigation for each county?

The main findings from this analysis that were statistically significant are as follows:

- In Anderson County, melanomas occurred less often than expected among males and females, and bladder cancer occurred more often than expected among males.
- In Blount County, lung, thyroid, and corpus uteri cancer occurred less often than expected among females, and melanomas occurred more often than expected among females.
- In Knox County, no type of cancer occurred more often than expected among females or males.
- In Loudon County, acute myeloid leukemia occurred more often than expected among females.
- In Meigs County, colon cancer occurred less often than expected among females.
- In Morgan County, colon and prostate cancers occurred less often than expected among males, and breast cancer occurred less often than expected among females.
- In Rhea County, cancer of the floor of the mouth and cancer of the small intestine occurred more often than expected among males, and cervical cancer occurred more often than expected among females.
- In Roane County, melanomas and prostate cancer occurred less often than expected among males, and pancreatic cancer occurred less often than expected among females. Kidney cancer occurred more often than expected among females.

2. Should the community be worried about these findings? What do they mean?

Although higher rates of certain cancers were found in several of the counties for which data were analyzed, no consistent pattern was observed in cancer occurrence. For this analysis, data on 42 cancer types were evaluated for the eight counties surrounding the Oak Ridge Reservation during the period 1991–2000. Given the large number of statistical analyses performed, it is not unusual to find some increases and some decreases in rates of occurrence.

These findings provide a picture of cancer in the population living in the eight counties surrounding the Oak Ridge Reservation. Although incidence rates of certain cancers were

higher in several counties than would be expected, the reasons for these increases are unknown and could be simply increased awareness and screening in these areas.

Also, community residents should be aware that scientific studies have identified a number of factors for various cancers which may increase an individual's risk of developing a specific type of cancer. These risk factors include such things as diet, age (cancer risk increases with age), family history, exposure to certain chemicals (only a limited number of chemicals show definite evidence of human carcinogenicity), exposure to radiation, alcohol use, and tobacco smoke. Appendix A contains information regarding the 10 most commonly reported cancers. Additional information on prevention, genetics, and causes of cancer can be found on the Web site of the National Cancer Institute (http://www.cancer.gov/cancertopics/prevention-genetics-causes).

3. Could the Oak Ridge facility be the cause of the higher number of cancers observed?

This analysis could not determine why people in the Oak Ridge area developed cancer, because (1) cancer takes time to develop, usually 20 to 40 years, (2) different types of cancer have different causes, and (3) the causes of most types of cancer are unknown. Scientific studies have identified risk factors for developing various cancers. Cancer risk factors include heredity, geographic area of residence, diet, environmental causes, tobacco smoke, sexual practices, and alcohol consumption.

4. Why did you standardize?

The reason for standardizing is to take into account differences among people in the population such as age, race, ethnicity, or sex to see if there are still elevated rates of a disease. In this analysis, we wanted to standardize because the counties we were concerned with may be very different demographically from the state of Tennessee as a whole, which was the comparison population, and we wanted to account for these differences. If we had not standardized, we would not have been able to draw meaningful conclusions from our analysis. For example, if we were to examine the cancer rates in a community predominantly of older people, we would expect higher rates because cancer is more common in older people. However, if our comparison population were predominantly younger, we would not expect much cancer. To get an accurate cancer rate, we must make adjustments for differences in age and/or other characteristics between the groups being compared.

5. Why do the results for Loudon County presented in this report differ from those presented in the public health assessment? (http://www2.state.tn.us/health/CEDS/list.htm)

The cancer analysis in the Loudon County public health assessment examined the crude rates of cancer incidence in the area and did not take into account differences due to age or race/ethnicity.

6. Why were the 49 census tracts surrounding the Oak Ridge Reservation not included in the analysis as requested by the Oak Ridge Reservation Health Effects Subcommittee?

A high percentage of the addresses for several counties were for either post office boxes or rural routes, which could not be geo-coded to the census tract level.

PREPARERS OF THE REPORT

Dhelia Williamson, Ph.D. Epidemiologist Surveillance and Registries Branch

Michael Lewin, M.S. Statistician Health Investigations Branch TABLES

Table 1: Number St	of Observed and E andardized Incider	Expected New Cancel ace Ratios, Anderso	er Cases, and Race- n County, 1991–200	and Age-Adjusted 00 ¹
		FEMALES	ii county, 1991 200	
Site	Observed	Expected	SIR*	95% CI
Anus	6	6.1	1.0	0.4 - 2.2
Bladder	39	43.8	0.9	0.6 - 1.2
Brain	18	22.1	0.8	0.5 - 1.3
Breast	578	519.9	1.1	1.0 - 1.2‡
Cervix	30	33.6	0.9	0.6 - 1.3
Colon	157	152.1	1.0	0.9 - 1.2
Corpus uteri	96	90.9	1.1	0.9 - 1.3
Esophagus	9	9.5	0.9	0.4 - 1.8
Gallbladder	8	4.8	1.7	0.7 - 3.3
Gum and other	8	9.6	0.8	0.4 - 1.6
mouth				
Hodgkin disease	11	9.9	1.1	0.6 - 2.0
Kidney	31	34.5	0.9	0.6 - 1.3
Larynx	15	12.1	1.2	0.7 – 2.0
Leukemia†				
AML	9	8.7	0.7	0.5 - 2.0
CLL	6	8.2	1.0	0.3 – 1.6
Lung and	241	244.5	1.0	0.9 – 1.1
bronchus				
Melanoma	8	31.0	0.3	0.1 - 0.5
Multiple	11	17.5	0.6	0.3 – 1.1
myeloma				
Non-Hodgkin	58	62.5	0.9	0.7 – 1.2
lymphoma				
Ovary	81	62.0	1.3	1.0 - 1.6‡
Pancreas	29	35.6	0.8	0.5 - 1.2
Rectum	38	44.2	0.9	0.6 - 1.2
Soft tissue	9	8.9	1.0	0.5 – 1.9
Stomach	17	15.5	1.1	0.6 - 1.8
Thyroid gland	40	31.7	1.3	0.9 – 1.7
Tongue	6	6.9	0.9	0.3 – 1.9

. 1. . . . _ _ . _ **.** .

¹ Cancers with ≤5 cases were not included in the analysis. * SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0. † CLL: chronic lymphocytic leukemia; AML: acute myeloid leukemia

Bold type indicates statistical significance. ‡ Borderline statistical significance

St	andardized Inciden	ce Ratios, Anderso	n County, 1991–200	00^{1}
		MALES		
Site	Observed	Expected	SIR*	95% CI
Bladder	147	112.0	1.3	1.1 – 1.5
Bones and joints	6	3.3	1.8	0.7 – 3.9
Brain	24	27.8	0.9	0.6 - 1.3
Colon	168	145.3	1.2	1.0 – 1.3‡
Esophagus	30	25.7	1.2	0.8 - 1.7
Gum and other mouth	7	7.0	1.0	0.4 – 2.1
Hodgkin disease	8	8.7	0.9	0.4 - 1.8
Hypopharynx	6	4.7	1.3	0.5 - 2.8
Kidney	47	51.2	0.9	0.7 – 1.2
Larynx	34	35.3	1.0	0.7 – 1.3
Leukemia†				
CLL	8	11.2	0.7	0.3 – 1.4
AML	7	8.8	0.8	0.3 – 1.6
Liver	8	9.0	0.9	0.4 – 1.7
Lung and bronchus	438	401.7	1.1	1.0 – 1.2‡
Melanoma	23	38.3	0.6	0.4 - 0.9
Multiple myeloma	18	18.9	1.0	0.6 - 1.5
Non-Hodgkin lymphoma	60	65.7	0.9	0.7 – 1.2
Pancreas	31	34.0	0.9	0.6 - 1.3
Prostate	483	478.3	1.0	0.9 – 1.1
Rectum	52	51.0	1.0	0.8 - 1.3
Small intestine	6	6.4	0.9	0.3 – 2.0
Soft tissue	9	10.2	0.9	0.4 – 1.7
Stomach	25	28.5	0.9	0.6 - 1.3
Testis	14	15.0	0.9	0.5 - 1.6
Thyroid gland	17	11.0	1.5	0.9 – 2.5
Tongue	8	10.5	0.8	0.3 – 1.5
Ureter	6	3.0	2.0	0.7 - 4.4

 Table 2: Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted

¹ Cancers with ≤5 cases were not included in the analysis. * SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0.

† CLL: chronic lymphocytic leukemia; AML: acute myeloid leukemia

Bold type indicates statistical significance.

Standardized Incidence Ratios, Blount County, 1991–2000 ¹					
		FEMALES			
Site	Observed	Expected	SIR*	95% CI	
Anus	7	8.4	0.8	0.3 – 1.7	
Bladder	53	57.9	0.9	0.7 - 1.2	
Bones and joints	8	4.7	1.7	0.7 – 3.3	
Brain	32	31.0	1.0	0.7 – 1.5	
Breast	678	717.9	0.9	0.9 – 1.0‡	
Cervix	40	48.3	0.8	0.6 - 1.1	
Colon	176	197.2	0.9	0.8 - 1.0‡	
Corpus uteri	92	123.5	0.7	0.6 - 0.9	
Esophagus	8	12.4	0.6	0.3 – 1.3	
Gum and other	17	12.3	1.4	0.8 - 2.2	
mouth					
Hodgkin disease	10	14.6	0.7	0.3 – 1.3	
Kidney	38	46.5	0.8	0.6 - 1.1	
Larynx	17	16.6	1.0	0.6 - 1.6	
Leukemia†					
ALL	11	6.8	1.6	0.8 - 2.9	
CLL	12	10.7	1.1	0.6 - 2.0	
AML	17	11.7	1.5	0.8 - 2.3	
CML	7	4.0	1.8	0.7 – 3.6	
Lung and bronchus	267	326.4	0.8	0.7 – 0.9	
Melanoma	67	43.8	1.5	1.2 - 1.9	
Multiple myeloma	27	22.9	1.2	0.8 - 1.7	
Non-Hodgkin	97	83.3	1.2	0.9 - 1.4	
lymphoma					
Ovary	69	85.1	0.8	0.6 – 1.0‡	
Pancreas	51	46.1	1.1	0.8 - 1.5	
Rectum	49	58.9	0.8	0.6 - 1.1	
Soft tissue	9	12.2	0.7	0.3 – 1.4	
Stomach	15	20.1	0.7	0.4 - 1.2	
Thyroid gland	30	47.0	0.6	0.4 - 0.9	
Tongue	10	9.4	1.1	0.5 - 2.0	

 Table 3: Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted

¹ Cancers with \leq 5 cases were not included in the analysis.

* SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0. † ALL: acute lymphocytic leukemia; CLL: chronic lymphocytic leukemia; CML: chronic myeloid leukemia;

AML: acute myeloid leukemia

Bold type indicates statistical significance.

Table 4: Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Blount County, 1991–2000 ¹				
		MALES	,	
Site	Observed	Expected	SIR*	95% CI
Bladder	147	151.7	1.0	0.8 - 1.1
Brain	51	40.9	1.2	0.9 – 1.6
Colon	171	196.9	0.9	0.7 – 1.0‡
Esophagus	44	35.7	1.2	0.9 – 1.7
Eye	6	5.3	1.1	0.4 - 2.5
Floor of mouth	7	7.3	1.0	0.4 - 2.0
Gum and other	9	9.9	0.9	0.4 - 1.7
mouth				
Hodgkin disease	18	15.9	1.1	0.7 – 1.8
Hypopharynx	7	6.7	1.0	0.4 - 2.1
Kidney	77	71.8	1.1	0.8 - 1.3
Larynx	55	49.8	1.1	0.8 - 1.4
Leukemia†				
ALL	11	8.3	1.3	0.7 - 2.4
CLL	14	15.2	0.9	0.5 – 1.5
AML	12	12.2	1.0	0.5 – 1.7
CML	10	5.3	1.9	0.9 - 3.5
Lip	6	7.0	0.9	0.3 – 1.9
	8	12.4	0.6	0.3 – 1.3
Liver				
Lung and bronchus	496	549.4	0.9	0.8 - 1.0‡
Melanoma	67	54.3	1.2	1.0 - 1.6‡
Multiple myeloma	30	25.2	1.2	0.8 - 1.7
Non-Hodgkin	80	91.9	0.9	0.7 – 1.1
lymphoma				
Pancreas	55	46.5	1.2	0.9 – 1.5
Prostate	620	646.5	1.0	0.9 - 1.0‡
Rectum	66	70.4	0.9	0.7 - 1.2
Small intestine	8	8.9	0.9	0.4 - 1.8
Soft tissue	9	14.2	0.6	0.3 - 1.2
Stomach	36	39.0	0.9	0.6 - 1.3
Testis	26	24.4	1.1	0.7 – 1.6
Thyroid gland	13	16.2	0.8	0.4 - 1.4
Tongue	7	15.0	0.5	0.2 - 1.0‡

¹Cancers with \leq 5 cases were not included in the analysis.

* SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0

† ALL: acute lymphocytic leukemia; CLL: chronic lymphocytic leukemia; AML: acute myeloid leukemia;
 CML: chronic myeloid leukemia

FEMALES Site Observed Expected SIR* 95% CI Anus 34 27.2 1.3 0.9 – 1.7 Bladder 196 188.4 1.0 0.9 – 1.2 Bones and 15 16.0 0.9 0.5 – 1.5 Joints 10 102.0 1.1 0.9 – 1.3 Breast 2468 2378 1.1 1.0 – 1.1‡ Cervix 165 173.8 0.9 0.8 – 1.1 Colon 698 656.6 1.1 1.0 – 1.1‡ Corpus uteri 434 404.8 1.1 1.0 – 1.2‡ Esophagus 47 43.3 1.1 0.8 – 1.4 Floor of Mouth 9 8.9 1.0 0.5 – 1.9 Gallbladder 17 20.0 0.8 0.5 – 1.4 Gum and other 35 40.2 0.9 0.6 – 1.2 mouth - - - - - Hodgkin 62 55.2
Site Observed Expected SIR* 95% CI Anus 34 27.2 1.3 0.9 – 1.7 Bladder 196 188.4 1.0 0.9 – 1.2 Bones and 15 16.0 0.9 0.5 – 1.5 Joints - - - - Brain 110 102.0 1.1 0.9 – 1.3 Breast 2468 2378 1.1 1.0 – 1.1‡ Cervix 165 173.8 0.9 0.8 – 1.1 Colon 698 656.6 1.1 1.0 – 1.1‡ Corpus uteri 434 404.8 1.1 1.0 – 1.2‡ Esophagus 47 43.3 1.1 0.8 – 1.4 Floor of Mouth 9 8.9 1.0 0.5 – 1.9 Gallbladder 17 20.0 0.8 0.5 – 1.4 Gum and other 35 40.2 0.9 0.6 – 1.2 mouth - - - - -
SiteObservedExpectedSIR*95% CIAnus3427.21.3 $0.9 - 1.7$ Bladder196188.41.0 $0.9 - 1.2$ Bones and1516.0 0.9 $0.5 - 1.5$ JointsBrain110102.01.1 $0.9 - 1.3$ Breast246823781.1 $1.0 - 1.1$ ‡Cervix165173.8 0.9 $0.8 - 1.1$ Colon698656.61.1 $1.0 - 1.2$ ‡Esophagus4743.31.1 $0.5 - 1.9$ Gallbladder1720.0 0.8 $0.5 - 1.4$ Floor of Mouth9 8.9 1.0 $0.5 - 1.9$ Gallbladder1720.0 0.8 $0.5 - 1.4$ Hodgkin6255.21.1 $0.9 - 1.2$ Larynx5357.0 0.9 $0.7 - 1.2$ Leukemia†4134.41.2 $0.9 - 1.6$
Anus3427.21.3 $0.9 - 1.7$ Bladder196188.41.0 $0.9 - 1.2$ Bones and1516.0 0.9 $0.5 - 1.5$ Joints100102.01.1 $0.9 - 1.3$ Brain110102.01.1 $0.9 - 1.3$ Breast246823781.1 $1.0 - 1.1$ ‡Cervix165173.8 0.9 $0.8 - 1.1$ Colon698656.61.1 $1.0 - 1.2$ ‡Esophagus4743.31.1 $0.8 - 1.4$ Floor of Mouth9 8.9 1.0 $0.5 - 1.9$ Gallbladder1720.0 0.8 $0.5 - 1.4$ Gum and other3540.2 0.9 $0.6 - 1.2$ mouth160156.1 1.0 $0.9 - 1.2$ Larynx5357.0 0.9 $0.7 - 1.2$ Leukemia†2222.6 1.0 $0.6 - 1.5$ CLL4134.4 1.2 $0.9 - 1.6$
Bladder196188.41.0 $0.9 - 1.2$ Bones and Joints1516.0 0.9 $0.5 - 1.5$ Brain110102.01.1 $0.9 - 1.3$ Breast246823781.1 $1.0 - 1.1$ ‡Cervix165173.8 0.9 $0.8 - 1.1$ Colon698656.61.1 $1.0 - 1.1$ ‡Corpus uteri434404.81.1 $1.0 - 1.2$ ‡Esophagus4743.31.1 $0.8 - 1.4$ Floor of Mouth9 8.9 1.0 $0.5 - 1.9$ Gallbladder1720.0 0.8 $0.5 - 1.4$ Gum and other3540.2 0.9 $0.6 - 1.2$ mouthHodgkin6255.21.1 $0.9 - 1.4$ Leukemia†ALL2222.61.0 $0.6 - 1.5$ CLL4134.41.2 $0.9 - 1.6$
Bones and Joints1516.0 0.9 $0.5 - 1.5$ Brain110102.01.1 $0.9 - 1.3$ Breast246823781.1 $1.0 - 1.1^{\ddagger}_{+}$ Cervix165173.8 0.9 $0.8 - 1.1$ Colon698656.61.1 $1.0 - 1.1^{\ddagger}_{+}$ Corpus uteri434404.81.1 $1.0 - 1.2^{\ddagger}_{+}$ Esophagus4743.31.1 $0.8 - 1.4$ Floor of Mouth9 8.9 1.0 $0.5 - 1.9$ Gallbladder1720.0 0.8 $0.5 - 1.4$ Gum and other3540.2 0.9 $0.6 - 1.2$ mouth160156.11.0 $0.9 - 1.4$ Hodgkin6255.21.1 $0.9 - 1.4$ Leukemia [†] 2222.6 1.0 $0.6 - 1.5$ CLL4134.41.2 $0.9 - 1.6$
JointsImage: space state stateImage: space state stateImage: space state stateBrain110102.01.1 $0.9 - 1.3$ Breast246823781.1 $1.0 - 1.1$ ‡Cervix165173.8 0.9 $0.8 - 1.1$ Colon698656.61.1 $1.0 - 1.1$ ‡Corpus uteri434404.8 1.1 $1.0 - 1.2$ ‡Esophagus4743.3 1.1 $0.8 - 1.4$ Floor of Mouth9 8.9 1.0 $0.5 - 1.9$ Gallbladder1720.0 0.8 $0.5 - 1.4$ Gum and other35 40.2 0.9 $0.6 - 1.2$ mouth160156.1 1.0 $0.9 - 1.4$ Hodgkin6255.2 1.1 $0.9 - 1.4$ Disease160156.1 1.0 $0.9 - 1.2$ Leukemia†2222.6 1.0 $0.6 - 1.5$ CLL4134.4 1.2 $0.9 - 1.6$
Brain110102.01.1 $0.9 - 1.3$ Breast246823781.1 $1.0 - 1.1$ ‡Cervix165173.8 0.9 $0.8 - 1.1$ Colon698656.6 1.1 $1.0 - 1.1$ ‡Corpus uteri434404.8 1.1 $1.0 - 1.2$ ‡Esophagus4743.3 1.1 $0.8 - 1.4$ Floor of Mouth9 8.9 1.0 $0.5 - 1.9$ Gallbladder1720.0 0.8 $0.5 - 1.4$ Gum and other3540.2 0.9 $0.6 - 1.2$ mouthHodgkin6255.2 1.1 $0.9 - 1.4$ DiseaseKidney160156.1 1.0 $0.9 - 1.2$ Leukemia†2222.6 1.0 $0.6 - 1.5$ CLL4134.4 1.2 $0.9 - 1.6$
Breast246823781.1 $1.0-1.1$ ‡Cervix165173.80.9 $0.8-1.1$ Colon698656.61.1 $1.0-1.1$ ‡Corpus uteri434404.81.1 $1.0-1.2$ ‡Esophagus4743.31.1 $0.8-1.4$ Floor of Mouth98.9 1.0 $0.5-1.9$ Gallbladder1720.0 0.8 $0.5-1.4$ Gum and other3540.2 0.9 $0.6-1.2$ mouthHodgkin6255.2 1.1 $0.9-1.4$ DiseaseKidney160156.1 1.0 $0.9-1.2$ Larynx5357.0 0.9 $0.7-1.2$ Leukemia†2222.6 1.0 $0.6-1.5$ CLL4134.4 1.2 $0.9-1.6$
$\begin{array}{c c c c c c c c c c c c c c c c c c c $
$\begin{array}{c c c c c c c c c c c c c c c c c c c $
$\begin{array}{c c c c c c c c c c c c c c c c c c c $
$\begin{array}{c c c c c c c c c c c c c c c c c c c $
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $
Gallbladder 17 20.0 0.8 0.5 - 1.4 Gum and other 35 40.2 0.9 0.6 - 1.2 mouth 62 55.2 1.1 0.9 - 1.4 Hodgkin 62 55.2 1.1 0.9 - 1.4 Disease 160 156.1 1.0 0.9 - 1.2 Larynx 53 57.0 0.9 0.7 - 1.2 Leukemia† 22 22.6 1.0 0.6 - 1.5 CLL 41 34.4 1.2 0.9 - 1.6
Gum and other mouth3540.2 0.9 $0.6 - 1.2$ Hodgkin Disease6255.2 1.1 $0.9 - 1.4$ Kidney160156.1 1.0 $0.9 - 1.2$ Larynx5357.0 0.9 $0.7 - 1.2$ Leukemia† ALL2222.6 1.0 $0.6 - 1.5$ CLL4134.4 1.2 $0.9 - 1.6$
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$
Hodgkin Disease 62 55.2 1.1 $0.9 - 1.4$ Kidney160156.1 1.0 $0.9 - 1.2$ Larynx 53 57.0 0.9 $0.7 - 1.2$ Leukemia† ALL 22 22.6 1.0 $0.6 - 1.5$ CLL 41 34.4 1.2 $0.9 - 1.6$
Disease Image: Mark Mark Mark Mark Mark Mark Mark Mark
Kidney 160 156.1 1.0 0.9 - 1.2 Larynx 53 57.0 0.9 0.7 - 1.2 Leukemia† 22 22.6 1.0 0.6 - 1.5 CLL 41 34.4 1.2 0.9 - 1.6
Larynx 53 57.0 0.9 0.7 - 1.2 Leukemia† ALL 22 22.6 1.0 0.6 - 1.5 CLL 41 34.4 1.2 0.9 - 1.6
Leukemia† 22 22.6 1.0 0.6 - 1.5 CLL 41 34.4 1.2 0.9 - 1.6
ALL 22 22.6 1.0 0.6 - 1.5 CLL 41 34.4 1.2 0.9 - 1.6
CLL 41 34.4 1.2 0.9 – 1.6
AML 36 39.0 0.9 0.6 - 1.3
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Liver 39 30.6 1.3 0.9 – 1.7
Lung and 1188 1087 1.1 $1.0 - 1.2$
bronchus
$\begin{array}{c c c c c c c c c c c c c c c c c c c $
gland 150 142.9 1.1 0.0 1.2
Melanoma 159 143.8 1.1 $0.9 - 1.3$ Melticite 90 90.9 1.1 0.0 - 1.4
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Invertorina 10 0.0 1.2 Non Hodskin 286 272.1 1.0 0.0 1.2
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Over y 202 201.5 1.0 $0.9 - 1.1$ Pancreas 174 158.9 1.1 $0.9 - 1.3$

Table 5 (continued)

Rectum	192	190.3	1.0	0.9 - 1.2
Soft tissue	42	41.5	1.0	0.7 - 1.4
Small intestine	18	18.5	1.0	0.6 - 1.5
Stomach	72	67.7	1.1	0.8 – 1.3
Thyroid gland	165	159.1	1.0	0.9 – 1.2
Tongue	35	31.1	1.1	0.8 – 1.6
Ureter	11	9.3	1.2	0.6 - 2.1

¹ Cancers with ≤5 cases were not included in the analysis. * SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0.

[†] ALL: acute lymphocytic leukemia; CLL: chronic lymphocytic leukemia; AML: acute myeloid leukemia; CML: chronic myeloid leukemia

Bold type indicates statistical significance.

Table 6: Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Knox County, 1991, 2000 ¹					
MALES					
Site	Observed	Expected	SIR*	95% CI	
Anus	18	15.0	1.2	0.7 – 1.9	
Bladder	439	459.0	1.0	0.9 - 1.1	
Bones and joints	16	16.6	1.0	0.6 - 1.6	
Brain	129	131.3	1.0	0.8 - 1.2	
Breast	24	17.4	1.4	0.9 - 2.0	
Colon	645	615.8	1.0	1.0 - 1.1‡	
Esophagus	101	111.5	0.9	0.7 - 1.1	
Eye	19	15.9	1.2	0.7 – 1.9	
Floor of mouth	21	24.1	0.9	0.5 - 1.3	
Gallbladder	7	9.0	0.8	0.3 - 1.6	
Gum and other	28	31.2	0.9	0.6 - 1.3	
mouth					
Hodgkin	56	56.6	1.0	0.7 – 1.3	
Disease					
Hypopharynx	23	22.5	1.0	0.6 - 1.5	
Kidney	222	228.4	1.0	0.8 - 1.1	
Larynx	160	159.7	1.0	0.9 – 1.2	
Leukemia†					
ALL	28	28.0	1.0	0.7 - 1.4	
CLL	53	47.8	1.1	0.8 - 1.5	
AML	40	38.6	1.0	0.7 – 1.4	
CML	16	17.1	0.9	0.5 - 1.5	
Lip	28	21.2	1.3	0.9 – 1.9	
Liver	42	40.0	1.1	0.8 - 1.4	
Lung and	1719	1716	1.0	1.0 – 1.1‡	
bronchus					
Major salivary	24	22.3	1.1	0.7 – 1.6	
gland					
Melanoma	190	167.7	1.1	1.0 - 1.3‡	
Multiple	86	81.1	1.1	0.8 – 1.3	
myeloma					
Nasopharynx	10	10.3	1.0	0.5 - 1.8	
Non-Hodgkin	323	289.8	1.1	1.0 - 1.2‡	
lymphoma					
Oropharynx	11	7.5	1.5	0.7 – 2.6	
Pancreas	158	146.6	1.1	0.9 – 1.3	
Penis	8	10.4	0.8	0.3 – 1.5	

Table 6 (continued)

Prostate	2217	2045	1.1	1.0 - 1.1‡
Rectum	227	223.4	1.0	0.9 – 1.2
Small intestine	27	28.5	0.9	0.6 - 1.4
Soft tissue	61	48.7	1.3	1.0 – 1.6‡
Stomach	126	123.7	1.0	0.8 - 1.2
Testis	95	89.8	1.1	0.9 – 1.3
Thyroid gland	51	51.5	1.0	0.7 – 1.3
Tongue	62	50.9	1.2	0.9 – 1.6
Ureter	7	12.4	0.6	0.2 – 1.2

¹ Cancers with \leq 5 cases were not included in the analysis.

* SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0. † ALL: acute lymphocytic leukemia; CLL: chronic lymphocytic leukemia; AML: acute myeloid leukemia;

CML: chronic myeloid leukemia

Bold type indicates statistical significance.

Table 7: Number	of Observed and E	Expected New Cance	er Cases, and Race-	and Age-Adjusted
S	Standardized Incide	nce Ratios, Loudon	County, 1991–2000	$)^1$
		FEMALES	•	•
Site	Observed	Expected	SIR*	95% CI
Bladder	15	11.4	1.3	0.7 – 2.2
Brain	15	11.4	1.3	0.7 - 2.2
Breast	286	11.4	1.3	0.7 - 2.2
Cervix	13	14.4	0.9	0.5 - 1.5
Colon	84	80.0	1.0	0.8 - 1.3
Corpus Uteri	37	27.9	1.3	0.9 - 1.8
Esophagus	7	5.1	1.4	0.6 - 2.8
Gum and other	8	5.1	1.6	0.7 – 3.1
mouth				
Kidney	8	9.2	0.9	0.4 - 1.7
Leukemia†	16	8.5	1.9	1.1 - 3.0
AML				
Lung	134	138.2	1.0	0.8 - 1.1
Melanoma	11	17.1	0.6	0.3 – 1.2
Myeloma	6	4.8	1.3	0.5 - 2.7
Non Hodgkins;	18	17.5	1.0	0.6 - 1.6
Lymphoma				
Ovary	21	18.8	1.1	0.7 - 1.7
Pancreas	24	18.6	1.3	0.8 - 1.9
Rectum	34	24.7	1.4	1.0 - 1.9‡
Stomach	10	8.0	1.2	0.6 - 2.3
Thyroid gland	15	11.4	1.3	0.7 – 2.2

¹ Cancers with ≤ 5 cases were not included in the analysis. * SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0.

† AML: acute myeloid leukemia

Bold type indicates statistical significance. ‡ Borderline statistical significance

Table 8: Number	of Observed and E	expected New Canc	er Cases, and Race-	and Age-Adjusted
S		MALES	1 County, 1991–200	J
Site	Observed	Expected	SIR*	95% CI
Bladder	63	65.2	1.0	0.7 – 1.2
Brain	17	17.3	1.0	0.6 - 1.6
Colon	86	83.9	1.0	0.8 - 1.3
Esophagus	17	15.3	1.1	0.6 - 1.8
Gum and other mouth	9	4.2	2.1	1.0-4.0‡
Hodgkin Disease	7	6	1.2	0.5 – 2.4
Kidney	40	31.0	1.3	0.9 - 1.8
Larynx	19	21.7	0.9	0.5 - 1.4
Leukemia†				
CLL	6	6.5	0.9	0.3 - 2.0
AML	8	5.2	1.5	0.7 - 3.0
Liver	6	5.3	1.1	0.4 - 2.5
Lung and bronchus	238	243.2	1.0	0.9 – 1.1
Melanoma	24	22.8	1.1	0.7 – 1.6
Multiple myeloma	11	10.7	1.0	0.5 – 1.8
Non-Hodgkin lymphoma	41	38.8	1.1	0.8 - 1.4
Pancreas	18	19.8	0.9	0.5 - 1.4
Prostate	277	287.9	1.0	0.9 – 1.1
Rectum	33	30.4	1.1	0.7 – 1.5
Stomach	17	16.3	1.0	0.6 – 1.7
Testis	10	8.7	1.1	0.5 - 2.1
Thyroid gland	6	6.6	0.9	0.3 - 2.0
Tongue	6	6.3	1.0	0.3 - 2.1

¹ Cancers with \leq 5 cases were not included in the analysis. * SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0.

† AML: acute myeloid leukemia; CLL: chronic lymphocytic leukemia

Bold type indicates statistical significance. ‡ Borderline statistical significance

Table 9: Number of Observed and Expected New Cancer Cases, and Race- and Age-Adjusted Standardized Incidence Ratios, Meigs County, 1991–2000 ¹					
		FEMALES			
Site	Observed	Expected	SIR*	95% CI	
Bladder	8	5.2	1.5	0.7 – 3.1	
Breast	58	68.0	0.9	0.6 – 1.1	
Cervix	9	4.6	1.9	0.9 – 3.7	
Colon	7	16.9	0.4	0.2 - 0.9	
Corpus uteri	12	11.6	1.0	0.5 - 1.8	
Lung	23	30.0	0.8	0.5 - 1.1	
Ovary	8	8.0	1.0	0.4 - 2.0	
Rectum	7	5.3	1.3	0.5 - 2.7	

1

¹ Cancers with ≤ 5 cases were not included in the analysis. * SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0. **Bold** type indicates statistical significance.

Table 10: Nu	Table 10: Number of Observed and Expected New Cancer Cases, and Race- and Age-				
Adju	sted Standardized In	ncidence Ratios, M	eigs County, 1991–2	2000^{1}	
		MALES			
Site	Observed	Expected	SIR*	95% CI	
Bladder	12	14.7	0.8	0.4 - 1.4	
Brain	6	4.4	1.3	0.5 - 2.9	
Colon	14	19.3	0.7	0.4 - 1.2	
Esophagus	6	3.6	1.7	0.6 - 3.6	
Kidney	9	7.4	1.2	0.6 - 2.3	
Lung	44	56.1	0.8	0.6 – 1.1	
Melanoma	7	5.6	1.2	0.5 - 2.6	
Non-Hodgkin	7	9.4	0.7	0.3 – 1.5	
lymphoma					
Prostate	61	64.8	0.9	0.7 - 1.2	
Stomach	8	3.7	2.1	0.9 - 4.2	

¹ Cancers with \leq 5 cases were not included in the analysis. * SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0

Table 11: Number of Observed and Expected New Cancer Cases, and Race- and Age-						
Adjus	Adjusted Standardized Incidence Ratios, Morgan County, 1991–2000 ¹					
		FEMALES				
Site	Observed	Expected	SIR*	95% CI		
Bladder	6	9.0	0.7	0.2 - 1.5		
Breast	78	114.6	0.7	0.5 - 0.8		
Cervix	8	7.7	1.0	0.4 - 2.0		
Colon	25	29.7	0.8	0.5 - 1.2		
Corpus uteri	17	19.6	0.9	0.5 - 1.4		
Lung and	45	50.7	0.9	0.6 - 1.2		
bronchus						
Non- Hodgkin	12	13.0	0.9	0.5 – 1.6		
lymphoma						
Ovary	9	13.6	0.7	0.3 – 1.3		
Rectum	6	9.3	0.6	0.2 - 1.4		
Thyroid gland	7	7.9	0.9	0.4 - 1.8		

¹ Cancers with ≤ 5 cases were not included in the analysis. * SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0. **Bold** type indicates statistical significance.

Table 12: Number of Observed and Expected New Cancer Cases, and Race- and Age-							
Adjus	ted Standardized Ir	cidence Ratios, Mo	organ County, 1991-	-2000^{1}			
		MALES					
Site	Observed	Expected	SIR*	95% CI			
Bladder	25	25.4	1.0	0.6 - 1.5			
Brain	6	7.8	0.8	0.3 – 1.7			
Colon	18	33.4	0.5	0.3 – 0.9			
Kidney	10	12.8	0.8	0.4 - 1.4			
Lung and	90	94.5	1.0	0.8 - 1.2			
bronchus							
Melanoma	6	9.9	0.6	0.2 - 1.3			
Prostate	69	108.3	0.6	0.5 - 0.8			
Rectum	15	12.4	1.2	0.7 - 2.0			

¹ Cancers with ≤ 5 cases were not included in the analysis. * SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0. **Bold** type indicates statistical significance.

Table 13: Number of Observed and Expected New Cancer Cases, and Race- and Age-						
Adju	Adjusted Standardized Incidence Ratios, Rhea County, 1991–2000 ¹					
		FEMALES				
Site	Observed	Expected	SIR*	95% CI		
Bladder	12	15.3	0.8	0.4 - 1.4		
Brain	8	8.2	1.0	0.4 – 1.9		
Breast	157	186.5	0.8	0.7 – 1.0‡		
Cervix	24	12.3	1.9	1.2 - 2.9		
Colon	56	51.8	1.1	0.8 - 1.4		
Corpus uteri	31	32.3	1.0	0.7 - 1.4		
Kidney	14	12.1	1.2	0.6 – 1.9		
Lung and	70	84.8	0.8	0.6 – 1.0‡		
bronchus						
Melanoma	11	11.3	1.0	0.5 - 1.7		
Non-Hodgkin	26	21.8	1.2	0.8 - 1.7		
Lymphoma						
Ovary	23	22.2	1.0	0.7 - 1.6		
Pancreas	9	12.0	0.7	0.3 – 1.4		
Rectum	14	15.4	0.9	0.5 - 1.5		
Soft tissue	6	3.2	1.9	0.7 - 4.1		
Stomach	6	5.3	1.1	0.4 - 3.5		
Thyroid gland	14	12.2	1.1	0.6 - 1.9		

 Improve grand
 Improve grand

Table 14: Nu	mber of Observed	and Expected New	Cancer Cases, and I	Race- and Age-
Adju	usted Standardized	Incidence Ratios, R	hea County, 1991–2	2000*
		MALES	1	1
Site	Observed	Expected	SIR*	95% CI
Bladder	36	40.1	0.9	0.6 - 1.2
Brain	15	11.0	1.4	0.8 - 2.3
Colon	40	51.8	0.8	0.6 - 1.1
Esophagus	7	9.4	0.7	0.3 – 1.5
Floor of mouth	7	2.0	3.6	1.4 - 7.3
Hodgkin	7	4.3	1.6	0.7 – 3.4
Disease				
Kidney	16	19.2	0.8	0.5 – 1.4
Larynx	17	13.3	1.3	0.7 - 2.0
Leukemia†				
CLL	9	4.0	2.2	1.0 - 4.3‡
Lung and	163	146.6	1.1	0.9 – 1.3
bronchus				
Melanoma	17	14.3	1.2	0.7 – 1.9
Non-Hodgkin	21	24.4	0.9	0.5 – 1.3
lymphoma				
Pancreas	7	12.3	0.6	0.2 - 1.2
Prostate	142	172.5	0.8	0.7 - 1.0‡
Rectum	11	18.7	0.6	0.3 – 1.1
Small intestine	7	2.3	3.0	1.2 – 6.3
Stomach	11	10.3	1.1	0.5 - 1.9

¹ Cancers with ≤ 5 cases were not included in the analysis. * SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0.

† CLL: chronic lymphocytic leukemia

Bold type indicates statistical significance.

‡ Borderline statistical significance

Table 15: Number of Observed and Expected New Cancer Cases, and Race- and Age-						
Adjus	Adjusted Standardized Incidence Ratios, Roane County, 1990–2000 ¹					
	1	FEMALES	1	I		
		_				
Site	Observed	Expected	SIR*	95% CI		
Bladder	34	31.3	1.1	0.8 - 1.5		
Brain	9	16.2	0.6	0.3 – 1.1		
Breast	328	382.2	0.9	0.8 - 1.0‡		
Cervix	27	24.4	1.1	0.7 - 1.6		
Colon	87	105.8	0.8	0.7 – 1.0‡		
Corpus uteri	61	66.8	0.9	0.7 – 1.2		
Esophagus	6	6.6	0.9	0.3 - 2.0		
Gum and other	9	6.6	1.4	0.6 - 2.6		
mouth						
Hodgkin disease	9	7.1	1.3	0.6 - 2.4		
Kidney	38	25.0	1.5	1.1 - 2.1		
Larynx	12	9.0	1.3	0.7 - 2.3		
Lung and	173	179.6	1.0	0.8 - 1.1		
bronchus						
Melanoma	19	22.5	0.8	0.5 - 1.3		
Multiple	13	12.4	1.1	0.6 - 1.8		
myeloma						
Non-Hodgkin	31	44.6	0.7	0.5 - 1.0‡		
lymphoma						
Ovary	44	45.2	1.0	0.7 - 1.3		
Pancreas	13	25.0	0.5	0.3 – 0.9		
Rectum	40	31.9	1.3	0.9 – 1.7		
Soft tissue	7	6.3	1.1	0.4 - 2.3		
Stomach	10	10.7	0.9	0.4 - 1.7		
Thyroid gland	30	23.4	1.3	0.9 - 1.8		

 Improve grand
 50 25.4 1.5 0.9 = 1.6

 ¹ Cancers with ≤ 5 cases were not included in the analysis.
 *
 SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0.

 Bold type indicates statistical significance.
 ‡
 Borderline statistical significance

Table 16: Number of Observed and Expected New Cancer Cases, and Race- and Age- Adjusted Standardized Incidence Ratios, Roane County, 1991–2000 ¹					
		MALES	•		
Site	Observed	Expected	SIR*	95% CI	
Bladder	82	82.8	1.0	0.8 - 1.2	
Brain	14	21.6	0.6	0.4 - 1.1	
Colon	112	107.7	1.0	0.9 – 1.3	
Esophagus	18	19.5	0.9	0.5 - 1.5	
Hodgkin disease	7	7.8	0.9	0.4 - 1.8	
Kidney	40	39.2	1.0	0.7 – 1.4	
Larynx	26	27.2	1.0	0.6 - 1.4	
Leukemia†					
ALL	6	4.1	1.5	0.5 - 3.2	
CLL	6	8.3	0.7	0.3 – 1.6	
Liver	6	6.7	0.9	0.3 – 1.9	
Lung and	325	305.1	1.1	1.0 - 1.2‡	
bronchus					
Melanoma	8	29.0	0.3	0.1 - 0.5	
Multiple	10	13.9	0.7	0.3 – 1.3	
myeloma					
Non-Hodgkin	49	49.3	1.0	0.7 – 1.3	
lymphoma					
Pancreas	21	25.3	0.8	0.5 – 1.3	
Prostate	296	361.6	0.8	0.7 – 0.9	
Rectum	45	38.5	1.2	0.9 – 1.6	
Soft tissue	6	7.4	0.8	0.3 – 1.8	
Stomach	21	21.0	1.0	0.6 - 1.5	
Testis	10	11.3	0.9	0.4 - 1.6	
Thyroid gland	7	8.5	0.8	0.3 – 1.7	
Tongue	8	8.1	1.0	0.4 - 2.0	

 1 Cancers with ≤5 cases were not included in the analysis.

 * SIR: standardized incidence ratio; when the number of observed cases equals the number expected, the SIR=1.0.

 † ALL: acute lymphocytic leukemia, CLL: chronic lymphocytic leukemia

 Bold type indicates statistical significance.

 ‡ Borderline statistical significance

APPENDIX A

MOST COMMON TYPES OF CANCER

The Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review (CSR) is a report of the most recent cancer incidence, mortality, survival, prevalence, and lifetime risk statistics published annually by the Cancer Statistics Branch of the National Cancer Institute. According to the SEER results for 19982002, cancer of the prostate gland has become the most common type of cancer among both black and white males (see table below).Lung cancer and colorectal cancer are the second and third highest, respectively; for both black and white males. Bladder cancer is the fourth most commonly diagnosed cancer in white males, but ranks seventh for black males.

Breast cancer is by far the most common cancer among both black and white females. Lung cancer and colorectal cancer are the second and third highest cancers, respectively, among white females compared with ranks of third and second highest, respectively, for black females. The forth most common cancer for females is corpus uteri (endometrial) for both whites and blacks.

Black Males	White Males	Black Females	White Females
1. prostate gland	prostate gland	breast	breast
2. lung & bronchus	lung & bronchus	colon/rectum	lung & bronchus
3. colon/rectum	colon/rectum	lung & bronchus	colon/rectum
4. oral cavity & pharynx	urinary bladder	corpus uteri	corpus uteri
5. non-Hodgkin lymphoma	melanoma of skin	pancreas	non-Hodgkin lymphoma
6. kidney/renal	non-Hodgkin lymphoma	cervix	melanoma of skin
7. urinary bladder	kidney/renal	non-Hodgkin lymphoma	ovary
8. stomach	leukemia	ovary	thyroid
9. pancreas	oral & pharynx	kidney/renal	urinary bladder
10. leukemia	pancreas	stomach	leukemia

10 Most Commonly Diagnosed Cancers as Measured by Number of Incident Cancer Cases, 1998–2002 By Race and Gender*

• National Cancer Institute. Surveillance, Epidemiology and End Results (SEER), Cancer Statistics Review 1975-2002.

[•] http://www.seer.cancer.gov/cgi-bin/csr/1975_2002/search.pl#results.

APPENDIX B

•



APPENDIX C

LIST OF CANCER SITES INCLUDED IN ANALYSIS

- 1. acute lymphocytic leukemia
- 2. acute myeloid leukemia
- 3. anus
- 4. bladder
- 5. bones and joints
- 6. brain
- 7. breast
- 8. cervix
- 9. chronic lymphocytic leukemia
- 10. chronic myeloid leukemia
- 11. colon (excluding rectum)
- 12. corpus uteri
- 13. esophagus
- 14. eye
- 15. floor of mouth
- 16. gallbladder
- 17. gum and other mouth
- 18. Hodgkin disease
- 19. hypopharynx
- 20. kidney
- 21. larynx
- 22. lip
- 23. liver
- 24. lung and bronchus
- 25. major salivary gland
- 26. melanomas
- 27. multiple myeloma
- 28. nasopharynx
- 29. non-Hodgkin lymphoma
- 30. oropharynx
- 31. ovary
- 32. pancreas
- 33. penis
- 34. prostate
- 35. rectum and rectosigmoid
- 36. soft tissue
- 37. small intestine
- 38. stomach
- 39. testis
- 40. thyroid gland
- 41. tongue
- 42. ureter

APPENDIX D

METHODS FOR ANALYZING AND INTERPRETING CANCER INCDIENCE DATA

A standardized incidence ratio (SIR) is the ratio of the incident number of cases of a specified condition in the study population to the incident number that would be expected if the study population had the same incidence rate as a standard or other population for which the incidence rate is known. Standardization (or adjustment) helps control for demographic differences between populations being compared. Standardized incidence rates estimate what the incidence rates for populations would be if their composition were similar to that of a comparison, or standard, population (and, therefore, to each other). Adjustment can be made for various characteristics that influence incidence rates, including age, race or ethnicity, and gender.

Although an unadjusted (or crude rate) is a valuable summary measure, comparison of crude rates between populations can be problematic if demographic characteristics, such as age distribution, that affect health outcome differ between the populations. The overall crude incidence rate for a population depends on not only the incidence rate for each age group but also the proportion of people in each age group. Age-adjustment helps control for differences in the age distribution of populations. Age-adjusted incidence rates for two populations are calculated by multiplying the incidence rates for each age group by the proportion of people in the same age group in the standard population. The sum of these products is the age-adjusted, or age-standardized, incidence rate for each of the populations.

Statistical significance implies that less than a certain percent chance (usually selected as 5%) exists that the observed difference is merely the result of random fluctuation in the number of observed cancer cases. Statistical significance can be determined by examining the confidence interval, which is the computed interval with a given probability (usually 95%) that the true value of an estimate is contained within the interval. For example, if the confidence interval does not include 1.0 and the interval is below 1.0, then the number of cases is significantly lower than expected. Similarly, if the confidence interval does not include 1.0, then a significant excess exists in the number of cases. If the confidence interval includes 1.0, then the true ratio may be 1.0, and the conclusion cannot be made with sufficient confidence that the observed number of cases reflects a real excess or deficit. As long as the 95% confidence interval contains 1.0, the indication is that the SIR is still within the range expected on the basis of the disease experience of the comparison population.

The width of the confidence interval also reflects the stability of the ratio estimate. For example, a narrow confidence interval (e.g., 1.03-1.15) allows a fair level of certainty that the calculated ratio is close to the true ratio for the population. A wide interval (e.g., 0.85-4.50) leaves considerable doubt about the true ratio, which could be much lower or much higher than the calculated ratio.

BIBLIOGRAPHY

Breslow NE, Day NE. 1980. Statistical methods in cancer research: volume 2. London: IARC Scientific Publications, No. 32. p. 48-49.

Last JM. A Dictionary of Epidemiology. Oxford University Press: New York, New York. 1983.

National Cancer Institute. In: Cancer rates and risks. NIH Publication No. 96-691. Bethesda: US Department of Health and Human Services; 1996, p. 203-205.

Rothman KJ. Epidemiology: An Introduction. Oxford University Press: New York, New York. 2002.